HistoSonics raised $102M in a Series D funding round led by Alpha Wave Ventures to scale the launch of its non-invasive histotripsy platform.
HistoSonics raised $102M in a Series D funding round led by Alpha Wave Ventures to scale the launch of its non-invasive histotripsy platform.
08/15/24, 12:16 PM
Location
plymouthMoney raised
$102 million
Industry
healthcare
medical device
medical
Round Type
series d
Investors
State Of Wisconsin Investment Board, Yonjin Venture, Lumira Ventures, Venture Investors, Johnson & Johnson Innovation Jjdc, Inc., Health Quest Capital, Amzak Health, Alpha Wave Ventures
HistoSonics has completed an oversubscribed $102 million Series D financing to enhance its histotripsy platforms and support commercial growth. This funding will also initiate the company’s innovative BOOMBOX Master Study evaluating their Edison System for liver tumor treatment.
Company Info
Location
16305 36th avenue north, suite 300
plymouth, minnesota, united states
Additional Info
HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform deliverers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today’s interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.